Results 101 to 110 of about 5,903 (227)

Prognostic significance of frequent CLDN18-ARHGAP26/6 fusion in gastric signet-ring cell cancer

Nature Communications, 2018
Signet-ring cell carcinoma (SRCC) is a unique type of gastric cancer with no prognostic features. Here, the authors report a CLDN18-ARHGAP26/6 gene fusion in patients with a high signet-ring cell content, poor survival outcomes, and who experience no ...
Yang Shu, Weihan Zhang, Qianqian Hou, Linyong Zhao, Shouyue Zhang, Jiankang Zhou, Xiaohai Song, Yan Zhang, Dan Jiang, Xinzu Chen, Peiqi Wang, Xuyang Xia, Fei Liao, Dandan Yin, Xiaolong Chen, Xueyan Zhou, Duyu Zhang, Senlin Yin, Kun Yang, Jianping Liu, Leilei Fu, Lan Zhang, Yuelan Wang, Junlong Zhang, Yunfei An, Hua Cheng, Bin Zheng, Hongye Sun, Yinglan Zhao, Yongsheng Wang, Dan Xie, Liang Ouyang, Ping Wang, Wei Zhang, Meng Qiu, Xianghui Fu, Lunzhi Dai, Gu He, Hanshuo Yang, Wei Cheng, Li Yang, Bo Liu, Weimin Li, Biao Dong, Zongguang Zhou, Yuquan Wei, Yong Peng, Heng Xu, Jiankun Hu   +48 more
doaj   +1 more source

The Impact of Upfront DihydroPyrimidine Dehydrogenase (DPD) Testing on the Therapeutic Management of Patients Scheduled for 5‐FU

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Purpose 5‐fluorouracil (5‐FU) is catabolized by dihydropyrimidine dehydrogenase (DPD). DPD deficiency can trigger life‐threatening toxicities, and pretesting DPD is increasingly recommended. Here, we investigated the impact of upfront DPD testing on treatment strategy, that is, whether DPD status influences physicians' choice to use 5‐FU or ...
Govind Kallee, Sébastien Salas, Gérard Milano, Florence Duffaud, Laetitia Dahan, Joseph Ciccolini   +5 more
wiley   +1 more source

Fluoropyrimidine-associated gastrointestinal toxicity: pharmacovigilance reporting signals and in vitro evidence of epithelial injury, barrier impairment, and inflammatory responses

Frontiers in Immunology
IntroductionFluoropyrimidines, including 5-fluorouracil (5-FU), capecitabine, tegafur, and trifluridine, are widely used anticancer agents, but their gastrointestinal toxicities remain clinically important.
Xinchi Luan, Xiaoran Li, Xiaoxuan Li, Xuezhe Wang, Xiaolei Zhang, Bangshen Zhao, Jia Xu, Zhanghao Yu, Guo Jing, Ning Liu   +9 more
doaj   +1 more source

Sintilimab Combined With Albumin‐Bound Paclitaxel and SOX Regimen as Conversion Therapy for Unresectable Advanced Gastric Cancer Achieving Complete Remission: A Case Report and Literature Review

Clinical Case Reports, Volume 14, Issue 9, September 2026.
ABSTRACT For carefully selected patients with unresectable advanced gastric cancer, immunochemotherapy combining PD‐1 inhibitor with albumin‐bound paclitaxel and S‐1/oxaliplatin may achieve deep remission and enable successful R0 resection. Our findings suggest that this multimodal conversion approach could be considered in selected cases with ...
Yufan Tang, Boquan Zhou, Bingbing Wen, Ke Yu, Jiajia Jia, Ying Sha, Jixiang Liu, Luyao Li, Ruifang Fan   +8 more
wiley   +1 more source

Déficit en Dihydropyrimidine Déshydrogénase et Toxicités aux Fluoropyrimidines au Cameroun : Étude Préliminaire

Health Research in Africa
RÉSUMÉ Introduction. Les fluoropyrimidines sont des agents cytotoxiques de première ligne dans les cancers solides. Leur toxicité, parfois sévère voire létale, peut être liée à un déficit en dihydropyrimidine déshydrogénase (DPD), enzyme clé de leur ...
Dina Bell Esther Hortense Murielle, Anaba Dominique, Atenguena Okobalemba Etienne, Maïson Mayeh Anne, Esson Mapoko Berthe, Sango Anne Juliette Flora, Atenguena Okobalemba Etienne, Moukoussa Diane Larissa, Mananga Jean Charles, Eboumbou Moukoko Carole Else   +9 more
doaj   +1 more source

First‐Line PD‐1 Inhibitor‐Based Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Revised Systematic Review and Meta‐Analysis of Phase III Trials

Cancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background and Purpose Immune checkpoint blockade has changed the first‐line treatment landscape for advanced esophageal squamous cell carcinoma (ESCC), but the magnitude and consistency of benefit across phase III trials require careful synthesis.
Vincent Rothweiler, Christoph Roderburg, Muemtaz Koeksal, Björn Erik Ole Jensen, Torsten Feldt, Ilyas Gencer, Johannes C. Fischer, Wilfried Budach, Wolfram Trudo Knoefel, Guangyu Lu, Edwin Bölke   +10 more
wiley   +1 more source

AZD6738 (Ceralasertib) Enhances Trifluridine's Antitumor Effect in 5‐FU–Resistant Colorectal Cancer Cells

Cancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background Resistance to 5‐fluorouracil (5‐FU) remains a major obstacle in colorectal cancer (CRC) treatment. Trifluridine (FTD), the active component of TAS‐102, exerts cytotoxicity through DNA incorporation and reportedly remains active in 5‐FU‐resistant tumors, though with limited clinical efficacy.
Shuhei Uehara, Takuya Suzuki, Junki Kato, Hiroyuki Asai, Akira Kato, Shinnosuke Harata, Hajime Ushigome, Yushi Yamakawa, Takahisa Hirokawa, Hiroki Takahashi, Yoichi Matsuo, Shuji Takiguchi   +11 more
wiley   +1 more source

Survival Outcomes With Cadonilimab Versus PD‐(L)1 Therapy in Front‐Line Gastric Cancer: A Network Meta‐Analysis

Cancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background The FDA Oncologic Drugs Advisory Committee (ODAC) highlighted that the risk–benefit profile for patients with low PD‐L1 expression remains unclear in front‐line treatment of HER2‐negative gastric and gastroesophageal junction (GC/GEJ) cancer with PD‐(L)1 therapy.
Zi‐Kun Yu, Jia‐Hong Yi, Ju Xue, Yu‐Chen Huang, Yue Zhao, Chang Jiang, Chen‐Xi Yin, Biao Xia, Yi‐Xin Zhou, Wen‐Zhuo He, Liang‐Ping Xia   +10 more
wiley   +1 more source

Global Investigation of Clinical Implementation Strategies for DPYD Testing to Guide Fluoropyrimidine Therapy

Clinical and Translational Science
Fluoropyrimidines are a vital component of chemotherapy regimens. Deleterious DPYD variants reduce activity of dihydropyrimidine dehydrogenase, the rate‐limiting enzyme of fluoropyrimidine catabolism, resulting in reduced fluoropyrimidine clearance and ...
Nihal El Rouby, Christina L. Aquilante, Salma A. Bargal, Larisa H. Cavallari, Julio D. Duarte, Kelly Gunderson, Tinashe Mazhindu, Mohamed Nagy, Xiaoyan Nie, D. Grace Nguyen, Jai N. Patel, Todd C. Skaar, D. Max Smith, Sony Tuteja, Ron H. N. vanSchaik, J. Kevin Hicks, The PGRN Implementation Working Group   +16 more
doaj   +1 more source

Prospective Phase II Trial of Biweekly Gemcitabine Plus Nab‐Paclitaxel as First‐Line Therapy in Patients Aged 75 Years and Older With Unresectable Pancreatic Cancer

Cancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background Although older adults (≥ 75 years) constitute a large proportion of patients with unresectable pancreatic cancer (PC), they remain underrepresented in clinical trials. Biweekly gemcitabine plus nab‐paclitaxel (GnP) has been evaluated in retrospective studies as an alternative dosing schedule, whereas prospective evidence remains ...
Kenji Ikezawa, Toshihiro Imai, Ryoji Takada, Takuo Yamai, Nobuyasu Fukutake, Makiko Urabe, Yugo Kai, Kaori Mukai, Tasuku Nakabori, Kazuyoshi Ohkawa   +9 more
wiley   +1 more source